Synthesis and glycosidase inhibitory activity of some N-substituted 5a-carba-β-fuco- and β-galactopyranosylamines, and selected derivatives

Bioorganic and Medicinal Chemistry

Volumn 12, Issue 24, 2004, Pages 6569-6579

  Ogawa, Seiichiro ^a   Fujieda, Shigeo ^a   Sakata, Yuko ^a   Ishizaki, Masahiro ^a   Hisamatsu, Seiichi ^a   Okazaki, Kensuke ^a   Ooki, Yoriko ^b   Mori, Midori ^b   Itoh, Masayoshi ^b   Korenaga, Takashi ^b  

^a KEIO UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN UNIVERSITY   (Japan)

Author keywords

Galactopyranosylamine; Glycosidase inhibitor

Indexed keywords

ALPHA GALACTOSIDASE; BETA GALACTOSIDASE; BETA GLUCOSIDASE; GLYCOSIDASE INHIBITOR; N (2 PHENYLETHYL) 5A CARBA BETA DEXTRO,LEVO FUCOPYRANOSYLAMINE; N (4 PHENYLBUTYL) 5A CARBA BETA LEVO FUCOPYRANOSYLAMINE; N BUTYL 5A CARBA BETA DEXTRO GALACTOPYRANOSYLAMINE; N DECYL 5A CARBA BETA DEXTRO GALACTOPYRANOSYLAMINE; N DECYL 5A CARBA BETA LEVO FUCOPYRANOSYLAMINE; N DODECYL 5A CARBA BETA DEXTRO GALACTOPYRANOSYLAMINE; N DODECYL 5A CARBA BETA LEVO FUCOPYRANOSYLAMINE; N HEXYL 5A CARBA BETA DEXTRO,LEVO FUCOPYRANOSYLAMINE; N OCTYL 5A CARBA BETA LEVO FUCOPYRANOSYLAMINE; N OCTYL 5A CARBA BETA LEVO GALACTOPYRANOSYLAMINE; UNCLASSIFIED DRUG;

ARTICLE; DRUG SYNTHESIS; ENZYME INHIBITION; INHIBITION KINETICS; STRUCTURE ACTIVITY RELATION;

BETA-GALACTOSIDASE; BETA-GLUCOSIDASE; GALACTOSAMINE; GLYCOSIDE HYDROLASES; INHIBITORY CONCENTRATION 50; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 20844444311     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2004.09.023     Document Type: Article

References (21)

1. S. Ogawa, M. Mori, G. Takeuchi, F. Doi, M. Watanabe, and Y. Sakata Bioorg. Med. Chem. Lett. 2002 811
2. S. Ogawa, R. Sekura, A. Maruyama, H. Yuasa, and H. Hashimoto Eur. J. Org. Chem. 2002 2089
3. S. Ogawa, M. Watanabe, A. Maruyama, and S. Hisamatsu Bioorg. Med. Chem. Lett. 12 2002 749
4. M. Takeuchi, K. Kamata, M. Yoshida, Y. Kameda, and K. Matsui J. Biochem. 108 1990 42
5. Y. Kameda, N. Takai, N. Asano, and K. Matsui Chem. Pharm. Bull. 38 1990 1970
6. S. Ogawa, S. Fujieda, Y. Sakata, M. Ishizaki, S. Hisamatsu, and K. Okazaki Bioorg. Med. Chem. Lett. 13 2003 3461
7. S. Ogawa, Y. Uematsu, S. Yoshida, N. Sasaki, and T. Suami J. Carbohydr. Chem. 6 1987 471
8. Other than compound l-12, the tri-O-benzyl and 1,2-O-isopropylidene derivatives were subjected to conventional conditions for epoxidation. Exclusive selectivity was obtained for l-12
9. Unless otherwise noted, when both racemic and optically active compounds were subjected to reaction, the processing for the latter were reported
10. H. Tsunoda, and S. Ogawa Liebigs Ann. Chem. 1994 103
11. S. Ogawa, K. Hirai, T. Odagiri, N. Matsunaga, T. Yamazaki, and A. Nakajima Eur. J. Org. Chem. 1998 1099
12. S. Ogawa, R. Sekura, A. Maruyama, T. Odagiri, H. Yuasa, and H. Hashimoto Carbohydr. Lett. 4 2000 13
13. H. Paulsen, and H. Koebernick Chem. Ber. 109 1976 104
14. S. Ogawa, and D. Aso Carbohydr. Res. 250 1993 177
15. All biological assays were carried out in a standard manner by Dr. Akihiro Tomoda (Hokko Chemical Industry, Co. Ltd)
16. J.N. Greul, M. Kleban, B. Schneider, S. Picasso, and V. Jäger ChemBioChem 2 2001 368 and references cited therein
17. G.L. Dickson, E. Leroy, and J.-L. Reymond Org. Biomol. Chem. 2 2004 1217 and references cited therein
18. T.M. Jespersen, W. Dong, M.R. Sierks, T. Skrydstrup, I. Lundt, and M. Bols Angew. Chem., Int. Ed. Engl. 33 1994 1778
19. Y. Ichikawa, Y. Igarashi, M. Ichikawa, and Y. Suhara J. Am. Chem. Soc. 120 1998 3007
20. N. Asano, A. Kato, K. Oseki, H. Kizu, and K. Matsui Eur. J. Biochem. 229 1995 369
21. Ogawa, S.; Funayama, S.; Okazaki, K.; Ishizuka, H.; Sakata, Y.; Doi, F. Bioorg. Med. Chem. Lett., in press